NuVasive (NUVA) aims to speed up the adoption of less invasive spine surgery through robotics.
If you own shares in Neurotrope, Inc. (NASDAQ:NTRP) then it's worth thinking about how it contributes to the...
Boston Scientific (BSX) is hopeful about robust data outcome on DAPT study as the therapy duration might prove to be a superior treatment option.
Neurotrope, Inc. (Nasdaq: NTRP) ("Neurotrope" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, today announced its corporate update.
Bruker's (BRKR) collaboration with Murdoch University will support International Centre of Excellence in metabolic phenotyping.
Article URL: https://www.quiverquant.com/sources/senatetrading Comments URL: https://news.ycombinator.com/item?id=23133624 Points: 2 # Comments: 0
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
NEW YORK, May 26, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) today announced that it will host an investor conference call and webcast to give an update on Bryostatin and the recently proposed merger between Neurotrope and Metuchen Pharmaceuticals, …
Neurotrope, Inc. (Nasdaq: NTRP) today announced that it will host an investor conference call and webcast to give an update on Bryostatin and the recently proposed merger between Neurotrope and Metuchen Pharmaceuticals, L.L.C. to form Petros Pharmaceuticals, …
The Company has made plans for a smooth transition. Mr. Weinstein is a finance and accounting senior executive with over 30 years of “hands-on” public and private company management, investment banking and private equity investing experience.
Natera (NTRA) is likely to maintain the current high on a number of favorable factors.
Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company ("Metuchen"), focused on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health conditions, today announced that the two companies have entered into a definitive merger agreement under which Metuchen and Neurotrope, Inc. ("Neurotrope") will merge in an all-stock transaction resulting in a newly formed holding company to be renamed Petros Pharmaceuticals, Inc. ("Petros"). Petros is expected to become a Nasdaq traded company focused solely on men's health conditions. Petros' cornerstone product would be Metuchen's Stendra® (avanafil) for erectile dysfunction ("ED"). Petros' pipeline would include Metuchen's recently in-licensed product H-100 for Peyronie's disease, and it would include a business development program exploring various men's health products, including endothelial dysfunction, prostate cancer, psychosexual and psychosocial ailments, hormone health and substance use disorders.
NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, today announced its plans to explore strategic alternatives to maximize shareholder value. "Following the results from our Phase 2 study of Bryostatin-1 in Alzheimer's disease, we believe a review of strategic alternatives is an important step toward preserving and enhancing shareholder value," stated Dr. Charles S. Ryan, Neurotrope's Chief Executive Officer. There can be no assurance that the formal strategic review of alternatives will result in any successful transaction or other outcome.
NEW YORK and MANALAPAN TOWNSHIP, N.J., May 18, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company ("Metuchen"), focused on identifying, developing, acquiring, and commercializi…
Zynex (ZYXI) is likely to maintain the current high on a number of favorable factors.
Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company ("Metuchen"), focused on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health conditions, today announ…
Align Technology (ALGN) succeeds in consecutively delivering a solid spurt in Invisalign Technology volumes across the company's entire clientele.
NEW YORK, May 26, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) today announced that it will host an investor conference call and webcast to give an update on Bryostatin and the recently proposed merger between Neurotrope and Metuchen Pharmaceuticals, …
January is turning out to be a bit of a roller-coaster market for my main account. The last trade I took in the account on Wednesday in Neurotrope, Inc. (NASDAQ: NTRP) ended up netting me another $166 in the account.
Neurotrope, Inc. (the "Company") (NASDAQ:NTRP) today announced that it has received commitments from institutional investors and pre-existing high net worth individuals to purchase an aggregate of $18 million of the Company's securities in a registered direct offering.
This latest FDA approval of Medtronic's (MDT) Evolut PRO+ follows the last month's nod from the regulatory body for the Evolut TAVR system with regard to expanded indication.
Abbott (ABT) is upbeat about the latest clearance in its neuromodulation product portfolio.
NEW YORK, NY / ACCESSWIRE / May 20, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek ...
Neurotrope, Inc. (Nasdaq: NTRP) today announced that it will host an investor conference call and webcast to give an update on Bryostatin and the recently proposed merger between Neurotrope and Metuchen Pharmaceuticals, L.L.C. to form Petros Pharmaceuticals, Inc. The investor call is scheduled for Thursday, May 28, 2020 at 11:00 AM ET.
FDA's approval will enable Insulet (PODD) to boost its insulin management business.
Within Diabetes group, Medtronic (MDT) is seeing a strong adoption of the Guardian Connect Smart CGM system.
NEW YORK and MANALAPAN TOWNSHIP, N.J., May 18, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company ("Metuchen"), focused on identifying, developing, acquiring, and commercializi…